The effects of zinc supplementation on the metabolic factors in patients with non-alcoholic fatty liver disease: a randomized, double-blinded, placebo-controlled clinical trial
Seyed Mohammad Amin Rezaei,
Farzaneh Mohammadi,
Mohammad Hassan Eftekhari,
Fardad Ejtehadi,
Haleh Ghaem,
Nazanin Mohammadipoor
Affiliations
Seyed Mohammad Amin Rezaei
Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences
Farzaneh Mohammadi
Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences
Mohammad Hassan Eftekhari
Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences
Fardad Ejtehadi
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences
Haleh Ghaem
Non-Communicable Diseases Research Center, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences
Nazanin Mohammadipoor
Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences
Abstract Background Non-alcoholic fatty liver disease (NAFLD) is associated with metabolic factors including obesity, dyslipidemia, insulin resistance, oxidative stress, and elevated inflammatory factors. Zinc (Zn) supplementation has been investigated as a potential adjunctive therapy in managing NAFLD outcomes. Methods In this randomized, double-blinded, controlled clinical trial, 50 overweight or obese participants with NAFLD were randomized into 2 groups of 25 and received either 30 mg of daily Zn or a placebo for 8 weeks. Both groups were invited to follow a balanced energy-restricted diet and physical activity recommendations. Results Based on the between-group comparison, Zn supplementation caused a significant increase in the Zn level (P 0.05). Conclusion The results of the present study indicated that 8-week supplementation of 30 mg daily Zn may increase the Zn serum level and decline anthropometric parameters, AST, TC, and LDL-C in NAFLD patients, so further research is suggested in the future. Trial registration The trial was retrospectively registered at IRCT.ir as IRCT20191015045113N1 (December/8/2019).
